Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

被引：49
|
作者：
Zhu, Andrew X. [1 ]
Finn, Richard S. [2 ]
Galle, Peter R. [3 ]
Llovet, Josep M. [4 ,5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[3] Univ Med Ctr, Mainz, Germany
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[6] Kindai Univ, Osaka, Japan
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(19)30165-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E191 / E191
页数：1
相关论文
共 50 条
  • [31] Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
    Galle, Peter R.
    Kudo, Masatoshi
    Llovet, Josep M.
    Finn, Richard S.
    Karwal, Mark
    Pezet, Denis
    Kim, Tae-You
    Yang, Tsai-Sheng
    Zagonel, Vittorina
    Tomasek, Jiri
    Phelip, Jean Marc
    Touchefeu, Yann
    Koh, Su-Jin
    Stirnimann, Guido
    Wang, Chunxiao
    Ogburn, Kenyon
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort
    Finn, R.
    De Toni, E.
    Yau, T. C. C.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A.
    SWISS MEDICAL WEEKLY, 2020, : 27S - 27S
  • [33] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
    Ian Chau
    Joon Oh Park
    Baek-Yeol Ryoo
    Chia-Jui Yen
    Ronnie Poon
    Davide Pastorelli
    Jean-Frédéric Blanc
    Masatoshi Kudo
    Tulio Pfiffer
    Etsuro Hatano
    Hyun Cheol Chung
    Katerina Kopeckova
    Jean-Marc Phelip
    Giovanni Brandi
    Shinichi Ohkawa
    Chung-Pin Li
    Takuji Okusaka
    Yanzhi Hsu
    Paolo B. Abada
    Andrew X. Zhu
    British Journal of Cancer, 2018, 119 : 19 - 26
  • [34] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
    Kudo, Masatoshi
    Okusaka, Takuji
    Motomura, Kenta
    Ohno, Izumi
    Morimoto, Manabu
    Seo, Satoru
    Wada, Yoshiyuki
    Sato, Shinpei
    Yamashita, Tatsuya
    Furukawa, Masayuki
    Aramaki, Takeshi
    Nadano, Seijin
    Ohkawa, Kazuyoshi
    Fujii, Hirofumi
    Kudo, Toshihiro
    Furuse, Junji
    Takai, Hiroki
    Homma, Gosuke
    Yoshikawa, Reigetsu
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [35] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
    Chau, Ian
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Poon, Ronnie
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Kudo, Masatoshi
    Pfiffer, Tulio
    Hatano, Etsuro
    Chung, Hyun Cheol
    Kopeckova, Katerina
    Phelip, Jean-Marc
    Brandi, Giovanni
    Ohkawa, Shinichi
    Li, Chung-Pin
    Okusaka, Takuji
    Hsu, Yanzhi
    Abada, Paolo B.
    Zhu, Andrew X.
    BRITISH JOURNAL OF CANCER, 2018, 119 (01) : 19 - 26
  • [36] Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
    Llovet, J.
    Kudo, M.
    Kang, Y-K.
    Yen, C-J.
    Finn, R. S.
    Galle, P. R.
    Assenat, E.
    Motomura, K.
    Okusaka, T.
    Berg, T.
    Hsu, C-H.
    Ikeda, M.
    Hsu, Y.
    Liang, K.
    Widau, R.
    Schelman, W.
    O'Brien, L.
    Gao, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 293 - +
  • [37] Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
    Reig, Maria
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard
    Llovet, Josep M.
    Metti, Andrea L.
    Schelman, William R.
    Liang, Kun
    Wang, Chunxiao
    Widau, Ryan C.
    Abada, Paolo
    Zhu, Andrew X.
    LIVER INTERNATIONAL, 2021, 41 (03) : 598 - 607
  • [38] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
    Kudo, Masatoshi
    Hatano, Etsuro
    Ohkawa, Shinichi
    Fujii, Hirofumi
    Masumoto, Akihide
    Furuse, Junji
    Wada, Yoshiyuki
    Ishii, Hiroshi
    Obi, Shuntaro
    Kaneko, Shuichi
    Kawazoe, Seiji
    Yokosuka, Osamu
    Ikeda, Masafumi
    Ukai, Katsuaki
    Morita, Sojiro
    Tsuji, Akihito
    Kudo, Toshihiro
    Shimada, Mitsuo
    Osaki, Yukio
    Tateishi, Ryosuke
    Sugiyama, Gen
    Abada, Paolo Benjamin
    Yang, Ling
    Okusaka, Takuji
    Zhu, Andrew Xiuxuan
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) : 494 - 503
  • [39] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
    Masatoshi Kudo
    Etsuro Hatano
    Shinichi Ohkawa
    Hirofumi Fujii
    Akihide Masumoto
    Junji Furuse
    Yoshiyuki Wada
    Hiroshi Ishii
    Shuntaro Obi
    Shuichi Kaneko
    Seiji Kawazoe
    Osamu Yokosuka
    Masafumi Ikeda
    Katsuaki Ukai
    Sojiro Morita
    Akihito Tsuji
    Toshihiro Kudo
    Mitsuo Shimada
    Yukio Osaki
    Ryosuke Tateishi
    Gen Sugiyama
    Paolo Benjamin Abada
    Ling Yang
    Takuji Okusaka
    Andrew Xiuxuan Zhu
    Journal of Gastroenterology, 2017, 52 : 494 - 503
  • [40] Value of alpha-fetoprotein in hepatocellular carcinoma
    Lee, Wei-Chen
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
12345